Advances in research of belimumab for treatment of systemic lupus erythematosus in children
Wang Wen-bo
Di Ya-zhen
Abstract：Objective To review the efficacy,combination therapy,and safety of belimumab in treating childhood-onset sys-temic lupus erythematosus(cSLE)to provide a reference for applying belimumab in cSLE patients.Methods A thorough literature search was conducted across PubMed,Web of Science,Cochrane Library,Embase,CNKI,Weipu,and Wanfang databases for clinical trials on belimumab treatment for cSLE from January 2019 to July 2024.The included studies underwent systematic quality assess-ment and comprehensive analysis.Results Belimumab significantly improved the clinical remission rate,reduced disease activity,and enhanced immunological markers in cSLE patients.It effectively alleviated inflammation and organ function damage,showing notable benefits for those with severe complications.Combined with corticosteroids and immunosuppressants,it could markedly improve clinical symptoms and reduce the dosage of drugs.Meanwhile,belimumab showed good tolerability and acceptable side effects.Conclusion Belimumab exhibits considerable effectiveness and a favorable safety in cSLE patients.So it is a potential ef-fective drug for the treatment of cSLE.
Keywords：Systemic lupus erythematosus in childrenAutoimmunityImmunosuppressantBelimumab
Publication Date：2024-10-25
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：6( 679-684 )